GLP-1 Trends in 2025: Market Growth and New Approvals
What are the biggest GLP-1 trends in 2025?
Key trends include: explosive market growth (tirzepatide up 8% in Q3 2025), new drug approvals like higher-dose Rybelsus, pipeline drugs targeting multiple receptors (retatrutide), expanded indications for cardiovascular and kidney disease, and continued supply challenges driving innovation in manufacturing.
Market Growth and Dominance
GLP-1 medications have become the fastest-growing drug class in pharmaceutical history:
- Market size: Projected $100+ billion globally by 2030
- Tirzepatide growth: Prescriptions up 8% in Q3 2025 alone
- Patient demand: Estimated 30+ million eligible patients in the US
- Supply constraints: Ongoing shortages driving manufacturing expansion
See our 2025 shortage updates.
New Drug Approvals and Pipeline
Several exciting developments are in progress:
Recently Approved / In Review
- Higher-dose oral semaglutide: 25mg and 50mg Rybelsus for enhanced weight loss
- Zepbound (tirzepatide): Expanded cardiovascular indications
- Weekly oral GLP-1: Convenience improvements in development
Pipeline Drugs to Watch
- Retatrutide (Eli Lilly): Triple agonist (GIP/GLP-1/glucagon) showing 24%+ weight loss
- Orforglipron: Daily oral GLP-1, potential game-changer for convenience
- CagriSema (Novo): Semaglutide + cagrilintide combination
- Survodutide: Dual GLP-1/glucagon agonist for NASH and obesity
Compare current options: tirzepatide vs semaglutide.
Expanded Medical Indications
GLP-1 medications are being approved for additional conditions:
- Cardiovascular disease: Reduced MACE events by 20% (SELECT trial)
- Chronic kidney disease: Kidney protection benefits
- NASH/fatty liver: Significant liver fat reduction
- Sleep apnea: Weight loss improving symptoms
- Heart failure: Ongoing trials showing promise
Learn about cardiovascular benefits.
Access and Affordability Trends
Several developments are improving access:
- Insurance expansion: More employers covering weight loss medications
- Medicare advocacy: Growing push for Medicare coverage of anti-obesity medications
- Compounding: Legal compounded versions providing affordable access
- Telehealth: Expanded remote prescribing making access easier
- Manufacturing scale-up: Both Novo and Lilly investing billions in production
What's Next: 2025 and Beyond
Key predictions: Continued supply improvements by mid-2025, potential FDA approval of retatrutide in 2026, growing competition driving innovation, expanded insurance coverage, and increasing focus on combination therapies targeting multiple metabolic pathways.
Ready to Start Your Weight Loss Journey?
Get started with physician-guided GLP-1 treatment from the comfort of your home.
Get Started TodayWritten by Dr. Sarah Mitchell
MD, Obesity Medicine
Our team of healthcare professionals specializes in weight management and metabolic health, providing evidence-based information to help you make informed decisions about your health journey.